ai3Bio Launches With $48M to Target Th17 Cells in Autoimmunity

A new entrant in the immune reset race

Autoimmune drug developer ai3Bio has come out of stealth with $48 million in early venture funding 123. Its goal is unusual in the crowded "immune reset" field. Most efforts there focus on wiping out malfunctioning B cells. ai3Bio instead wants to eliminate a specific subset of inflammatory T cells 23.

The company's first disease targets are autoimmune disorders of the liver. These conditions have few treatment options, and in some cases none 2. The financing is meant to carry a pipeline that could enter human testing as early as next year 2.

Two biotechs, one company

ai3Bio was assembled from parts of two existing companies 3. Corner Therapeutics spun off its autoimmune technology, which was then merged with Novasenta, a biotech backed by the University of Pittsburgh 1. Investors backed what the company describes as complementary foundational technologies from each side 1.

Accounts of where the company is based differ:

• Fierce Biotech calls it Massachusetts-based 1.
• MedCity News places it in Watertown, Massachusetts 2.
• BioPharma Dive lists headquarters in both Pittsburgh and Watertown 3.

Given the company's origins, a two-city footprint seems the most plausible reading. The Pittsburgh side likely reflects Novasenta's university roots.

How the platform works

The science centers on Th17 cells. These are T helper cells that produce a cytokine that can drive harmful inflammation 3. ai3Bio pairs an AI-driven discovery engine with two technologies aimed at removing these cells, called StarX and T Deplete 1.

StarX is a lipid nanoparticle delivery system carrying an mRNA payload. It is directed to CD161, a surface marker found on Th17 cells in autoimmune disease 1. Once delivered, the payload triggers cell death 1. Fierce's coverage links the platform to the STING pathway, a component of the innate immune machinery 1.

MedCity News puts the strategy simply: rather than engineering one immune cell to hunt another, ai3Bio taps a built-in cellular pathway that pushes pathogenic cells to destroy themselves 2. Scientific co-founder Jonathan Kagan, a Harvard Medical School professor, said the company hopes to be the first able to deplete diseased T cells specifically 1. He described the aim as using current understanding of inflammation to guide the design of future drugs 1.

Why the approach matters

The immune reset concept has become one of immunology's busiest research areas. The idea is to clear out the immune cells driving autoimmune disease so the system can rebuild with cells that no longer attack the body 2. Many current approaches reprogram one type of immune cell to pursue and eliminate another 2. That category includes cell therapies adapted from cancer.

This is where ai3Bio's design could stand out. Cell-therapy approaches typically depend on manufacturing patient-specific cells and often on preparatory treatment before infusion. A lipid nanoparticle-delivered mRNA is, in principle, a more conventional drug-like product. If the targeting works as described, it could avoid some of that complexity, including the need for preconditioning. That would be a meaningful practical advantage, especially for chronic liver conditions where aggressive interventions are hard to justify.

Targeting T cells rather than B cells is also a bet on biology. B-cell depletion has drawn the most attention because antibody-driven diseases offer a clear rationale. Many autoimmune conditions, however, are driven heavily by T-cell inflammation. Tools that eliminate pathogenic T cells without broadly suppressing the immune system have been hard to build. A marker such as CD161, linked to disease-associated Th17 cells 1, offers a possible way to be selective. That selectivity is the core claim the company will need to prove.

What remains unproven

ai3Bio has not yet tested its therapies in humans, and none of the coverage reports clinical data. The key questions are typical of early platform companies:

• Specificity: Can the system distinguish diseased Th17 cells from healthy cells that also express CD161?
• Delivery: Will the lipid nanoparticles reach the right tissues efficiently?
• Safety: Will forcing cells to self-destruct trigger unwanted inflammation of its own?

Activating innate immune pathways to kill cells is a delicate balance, particularly in diseases defined by excess inflammation.

The $48 million raise is modest by the standards of immune reset startups. It is likely enough to reach first-in-human studies but not to carry a broad pipeline far beyond them.

The takeaway

ai3Bio enters a crowded field with a genuinely different angle: self-destructing T cells instead of engineered cell hunters, and liver autoimmunity instead of the more commonly pursued indications. Its potential for a simpler, injectable approach is the most compelling part of the pitch. Whether the company can show precise, safe depletion in patients will decide whether that difference amounts to a real advance.